Filing Flows › Akebia Therapeutics (AKBA) › How it makes money
How Akebia Therapeutics (AKBA) makes money
Akebia Therapeutics (AKBA) made $36.9M of revenue in the third quarter 2026 (Q3 2026), -37% from a year earlier. Product revenue, net brought in $34.8M (94%); License, collaboration and other revenue brought in $2.1M (6%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product revenue, net | $34.8M | 94.4% | -26% | -39% |
| ↳ Auryxia | $20.0M | 54.3% | -21% | -53% |
| ↳ Vafseo | $14.8M | 40.1% | -31% | +3% |
| License, collaboration and other revenue | $2.1M | 5.6% | -12% | +5% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $36.9M | 100.0% |
| Income tax | $175K | 0.5% |
| Operating cash flow | $2.3M | 6.3% |
| Free cash flow | $1.6M | 4.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $36.9M | -37% |
| Q2 2026 | $49.1M | -21% |
| Q1 2026 | $53.5M | -7% |
| Q4 2025 | $57.6M | +24% |
| Q3 2025 | $58.8M | +57% |
| Q2 2025 | $62.5M | +43% |
| Q1 2025 | $57.3M | +76% |
From Akebia Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Akebia Therapeutics make money?
Akebia Therapeutics (AKBA) made $36.9M of revenue in the third quarter 2026 (Q3 2026), -37% from a year earlier. Product revenue, net brought in $34.8M (94%); License, collaboration and other revenue brought in $2.1M (6%).
What is Akebia Therapeutics' biggest business?
Product revenue, net: $34.8M in the third quarter 2026, 94% of revenue, -39% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.